To access the full text documents, please follow this link: http://hdl.handle.net/2445/119018

Pilot study of living donor liver transplantation for patients with HCC exceeding Milan criteria
Llovet i Bayer, Josep Maria; Pavel, Mihai; Rimola, Jordi; Diaz, Maria Alba; Colmenero, Jordi; Saavedra, David; Fondevila Campo, Constantino; Ayuso Colella, Carmen; Fuster Obregón, Josep; Ginès i Gibert, Pere; Bruix Tudó, Jordi; García-Valdecasas Salgado, Juan Carlos
BACKGROUND & AIMS: A subset of patients with hepatocellular carcinoma (HCC) beyond Milan criteria might obtain acceptable survival outcomes after liver transplantation. Living donor liver transplantation (LDLT) has emerged as a feasible alternative to overcome the paucity of donors. METHODS: In 2001 we started a protocol for LDLT in Child A-B patients with HCC fulfilling a set of criteria - the BCLC expanded criteria- that expanded the conventional indications of transplantation: 1 tumor ≤ 7cm, 5 tumors ≤ 3cm, 3 tumors ≤ 5cm without macrovascular invasion or down-staging to Milan after loco-regional therapies. RESULTS: We present a prospective cohort of 22 patients with BCLC extended indications based on size/number (17) or down-staging (5) treated with LDLT between 2001 and 2014. Characteristics of the patients were as follows: median age: 57yr old; males/female: 20/2, Child-Pugh A/B: 16/6, AFP <100ng/mL: 21. Twelve patients received neo-adjuvant loco-regional therapies. At the time of transplantation, 12 patients had HCC staging beyond Milan criteria and 10 within. Pathological reports showed that 50% exceeded BCLC expanded criteria. Perioperative mortality was 0%. After a median follow up of 81 months, the 1-, 3-, 5- and 10-year survival was 95.5%, 86.4%, 80.2% and 66.8%, respectively. Overall, seven patients recurred (range 9-108 mo), and the 5-y and 10-yr actuarial recurrence rate was of 23.8% and 44,4%, respectively. CONCLUSION: A proper selection of candidates for extended indications of living donor liver transplantation for HCC patients provide survival outcomes comparable t
-Trasplantament hepàtic
-Pronòstic mèdic
-Càncer de fetge
-Hepatic transplantation
-Prognosis
-Liver cancer
(c) American Association for the Study of Liver Diseases, 2017
Article
Article - Accepted version
No longer published by Elsevier
         

Show full item record

Related documents

Other documents of the same author

Llovet i Bayer, Josep Maria; Pavel, Mihai; Rimola, Jordi; Diaz, Maria Alba; Colmenero, Jordi; Saavedra, David; Fondevila Campo, Constantino; Ayuso Colella, Carmen; Fuster Obregón, Josep; Ginès i Gibert, Pere; Bruix Tudó, Jordi; García-Valdecasas Salgado, Juan Carlos
Rimola, Jordi; Díaz González, Álvaro; Reig, María; Darnell, Anna; Varela, María; Pons, Fernando; Hernández Guerra, Manuel; Delgado, Manuel; Castroagudin, Javier; Matilla, Ana; Sangro, Bruno; Rodriguez de Lope, Carlos; Sala, Margarita; Gonzalez, Carmen; Huertas, Carlos; Minguez, Beatriz; Ayuso Colella, Carmen; Bruix Tudó, Jordi
Rimola, Jordi; Díaz González, Álvaro; Reig, María; Darnell, Anna; Varela, María; Pons, Fernando; Hernández Guerra, Manuel; Delgado, Manuel; Castroagudin, Javier; Matilla, Ana; Sangro, Bruno; Rodriguez de Lope, Carlos; Sala, Margarita; Gonzalez, Carmen; Huertas, Carlos; Minguez, Beatriz; Ayuso Colella, Carmen; Bruix Tudó, Jordi
Grau de Castro, Juan J.; Palmero, Ramon; Marmol, Maribel; Domingo-Domenech, José; Monzó Planella, Mariano; Fuster Obregón, Josep; Vidal, Oscar; Fondevila Campo, Constantino; García-Valdecasas Salgado, Juan Carlos
Llovet i Bayer, Josep Maria; Mas, X.; Aponte, John J.; Fuster Obregón, Josep; Navasa, Miquel; Christensen, E.; Rodés, J.; Bruix Tudó, Jordi
 

Coordination

 

Supporters